PROfound trial results now in NEJM : Olaparib improves PFS in #mCRPC patients with DNA Repair mutations after abi/enza failure #ProstateCancer #PrecisionMedicine nejm.org/doi/full/10.10…

Promising Phase I/II results move towards Phase III trial design using VERU-111 (α + β tubulin inhibitor) in men with #mCRPC after failure of novel androgen blockade: 75% with PSA response; 25% tumor response; 63% stable disease #ProstateCancer targetedonc.com/view/promising…

IMvigor130: Frontline Atezo + chemo improves PFS in metastatic urothelial carcinoma #bladdercancer great work by Matt Galsky and his team The Lancet thelancet.com/journals/lance…

FDA approves olaparib for men with HRR-mutant mCRPC after progression on abiraterone or enzalutamide (no prior chemo required) #prostatecancer onclive.com/web-exclusives…

⁦Dan Theodorescu⁩ ⁦@CSCancerCare⁩ says Cancer Doesn't Wait: Seek Care for Symptoms ⁦Cedars-Sinai⁩ ⁦The Angeles Clinic⁩ #losangeles #cancer #oncologist cedars-sinai.org/newsroom/cance…

#ASCO20 Nivo/IPI in mRCC #kidneycancer after prior PD-1/L1i Rx in FRACTION-RCC trial: ORR~15%👇Looking forward to talk by Toni Choueiri, MD Area of high unmet need. Data provide bench mark for future trials in this setting. Dana-Farber Kidney Cancer Weblink: bit.ly/36Ar3Kh

Intratumoral CD4+ T Cells Mediate Anti-tumor Cytotoxicity in Human Bladder Cancer: Cell | ⁦Dan Theodorescu⁩ ⁦Guru P. Sonpavde, MD⁩ cell.com/cell/fulltext/…

Cabozantinib shows single agent activity with 19% ORR in platinum-refractory metastatic urothelial carcinoma...solid backbone to build future combinations from thelancet.com/journals/lanon…

We are thrilled to be ranked the #7 #Cancer program in the nation by U.S. News & World Report! Cedars-Sinai has been ranked #7 in the Best Hospitals Honor Roll. Congratulations to all our amazing staff for this achievement! #CedarsSinaiCancer #BestHospitals health.usnews.com/best-hospitals…

Results reinforce my confidence in IOs in #ProstateCancer 👉🏻 Finally OS (pre-specified endpoint) is significantly higher with IPI in postdocetaxel mCRPC, in a phase 3 trial we started 10 yrs ago under #KarimFizazi leadership. bit.ly/2YcebHo OncoAlert Thanks European Urology

KEYNOTE-581: Pembro + Lenvatinib shows improved PFS, OS and ORR as frontline treatment for mRCC across all MSKCC risk groups when compared with sunitinib onclive.com/view/frontline…

Neoadjuvant combination PD-L1/CTLA-4 in cisplatin-ineligible operable high-risk bladder cancer showed pCR = 37.5% and downstaging to T1 or less in 58% of patients who completed surgery Society for Immunotherapy of Cancer #SITC2020 #sitc20 #bladdercancer nature.com/articles/s4159…

FDA approves Cabo/Nivo as first line treatment for advanced RCC for all risk categories adding another VEGF TKI/IO combo to the mix #kidneycancer news.bms.com/news/corporate…

Enfortumab Vedotin shows 40% overall response rate and reduces risk of death by 30% compared to chemotherapy in advanced urothelial carcinoma after chemotherapy and immunotherapy Tom Powles NEJM ASCO #bladdercancer #GU21

Excellent panel of radioligand experts led by Michael Hofman discussing the current landscape of PSMA theranostics in prostate cancer PCF Science #PCFRetreat #PCFRetreat21 Prostate Cancer Foundation

"mCRPC: the iatrogenic disease WE created"...What an amazingly inspirational and visionary talk by PCF Science new President & CEO Charles Ryan during Week 2 of #PCFRetreat21 Prostate Cancer Foundation Howard Soule

ASCO GU 2023 Day 1 Take Home: PARPi's! 1) TALAPRO-2: talazoparib (PARPi) + enzalutamide improved rPFS vs enzalutamide alone in 1st line mCRPC irrespective of HRR mutation status Neeraj Agarwal, MD, FASCO #ASCOGU23 #ascogu2023 #ASCOGU

ASCO GU 2023 Day 1 Take Home: PARPi's! 2) TRITON-3: rucaparib (PARPi) improved rPFS vs physicians choice (doce/abi/enza) in mCRPC with BRCA1/2 mutations after ARPi (abi/enza) progression Alan H Bryce #ASCOGU23 #ascogu2023 #ASCOGU

ASCO GU 2023 Day 1 Take Home: PARPi's! 3) PROpel: olaparib (PARPi) + abiraterone improved rPFS vs abiraterone alone in 1st line mCRPC irrespective of HRR status #ASCOGU23 #ascogu2023 #ASCOGU

Excited to tweet that as of this week our first patient with mCRPC has successfully been treated with the novel agent DZ-002 as part of the DaZen DZ-002-101 Phase I clinic trial The Angeles Clinic clinicaltrials.gov/ct2/show/NCT04… #prostatecancer #mCRPC #clinicaltrials